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Background: Myelofibrosis occurs as primary myelofibrosis or as a late occurrence in the evolution of essential
thrombocythaemia and polycythaemia vera. It is the rarest of the three classic myeloproliferative neoplasms (MPN).
Polyploidy has only rarely been reported in MPN despite the prominent involvement of abnormal megakaryocytes.
The use of peripheral blood samples containing increased numbers of haematopoietic progenitors has improved
the output from cytogenetic studies in myelofibrosis and together with the use of single nucleotide polymorphism
arrays (SNPa) has contributed to an improved knowledge regarding the diverse genetic landscape of this rare disease.
Results: Cytogenetic studies performed on a consecutive cohort of 42 patients with primary or post ET/PV
myelofibrosis showed an abnormal karyotype in 24 cases and of these, nine showed a polyploid clone. Six of the nine
cases showed a tetraploid (4n) subclone, whereas three showed mixed polyploid subclones with both tetraploid and
octoploid (4n/8n) cell lines. The abnormal clone evolved from a near diploid karyotype at the initial investigation to a
tetraploid karyotype in follow-up cytogenetic analysis in four cases. In total, six of the nine polyploid cases showed gain
of 1q material. The remaining three cases showed polyploid metaphases, but with no detectable structural karyotypic
rearrangements. Three of the nine cases showed chromosome abnormalities of 6p, either at diagnosis or later acquired.
SNPa analysis on eight polyploid cases showed additional changes not previously recognised by karyotype analysis
alone, including recurring changes involving 9p, 14q, 17q and 22q. Except for gain of 1q, SNPa findings from the
polyploid group compared to eight non-polyploid cases with myelofibrosis found no significant differences in the type
of abnormality detected.
Conclusions: The study showed the use of peripheral blood samples to be suitable for standard karyotyping evaluation
and DNA based studies. The overall profile of abnormalities found were comparable with that of post-MPN acute
myeloid leukaemia or secondary myelodysplastic syndrome and cases in the polyploidy group were associated with
features of high risk disease. The above represents the first documented series of polyploid karyotypes in myelofibrosis
and shows a high representation of gain of 1q.
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The classic myeloproliferative neoplasms (MPN) encom-
pass three disease subsets, including polycythaemia vera
(PV), essential thrombocythaemia (ET) and primary my-
elofibrosis (PMF). PMF occurs at an incidence of 0.3-1.5
per 100,000 and is characterised clinically by anaemia,
splenomegaly and progressive bone marrow (BM) fibro-
sis [1]. Thrombocytopenia or thrombocytosis is frequent
[2]. Morphologically, PMF patients typically show a leu-
koerythroblastic blood film, elevated numbers of circu-
lating CD34+ cells and the presence of prominent,
abnormal, dysplastic megakaryocytes in the BM [3]. Ap-
proximately 5% of ET and 20% of PV patients progress
to a secondary myelofibrosis (sMF), usually after a 15–
20 year follow up period. PMF may also transform to
acute leukaemia in 8-23% of cases in the first 10 years
post-diagnosis [4].
Abnormal karyotypes occur in approximately 50% of
PMF cases. Chromosome aberrations including +1q, +8,
del(12p), del(13q) and del(20q) are commonly reported
across all three MPN [5]. These structural chromosome
abnormalities and a variety of molecular defects including
gene mutations affecting JAK2, MPL, TET2, LNK, EZH2,
NF1, IDH1, IDH2, CBL, ASXL1, IKAROS and NF-E2 are
prevalent but not specific to any subset of MPN and
have been described in other myeloid disorders [6,7].
The underlying molecular pathogenesis driving fibrosis
remains unknown despite multiple studies to date
attempting to identify a common genetic defect [8]. This
has contributed to difficulties in developing effective
targeted therapies.
Polyploidy refers to an increased number of the complete
set of chromosomes and occurs in multiples of the haploid
set. Polyploidy may be found as a natural phenomenon in
some mammalian cells such as megakaryocytes and hepa-
tocytes or it may occur in relation to a pathological state.
Polyploidy in normal megakaryocyte precursors is achieved
by endomitosis whereby cells enter mitosis repeatedly
during cell cycling, do not complete mitosis but in-
stead re-enter G1 and proceed through S phase and
G2/M in repeated cycles. As a result of endomitosis
the cell is able to conserve energy while producing the
large numbers of anucleate platelets needed for normal
haemostasis [9].
Disruption of normal endomitosis influences megakar-
yocyte ploidy and platelet production and may result in
thrombocytopenia or thrombocytosis [10]. Patients with
MF show characteristic large, bizarre and dysplastic forms
of megakaryocytes that are clonal, but reports of polyploid
karyotypes in the literature are rare [11]. Studies suggest a
disruption in the normal mechanism for polyploidisation
during megakaryocyte growth in PMF leading to an in-
crease in megakaryocyte numbers but with reduced poly-
ploidy [12,13].The generation of polyploid and in particular tetra-
ploid karyotypes in neoplastic cells may involve different
mechanisms such as abortive mitosis, failure of cytokin-
esis or centrosome amplification. Tetraploidy has been
postulated as a precursor in the formation of stable an-
euploidy and in the development of chromosome in-
stability in cancer. An additional role in the suppression
of tumourigenesis in some scenarios makes tetraploidy a
possible therapeutic target [14,15].
In this study, the clinical and molecular cytogenetic
characteristics of nine patients showing a polyploid meta-
phase clone are discussed in detail. In addition, study of
the underlying mechanism for formation of the polyploid




Peripheral blood (PB) and BM samples were obtained
from 42 patients with myelofibrosis (MF) associated with
MPN between July 2006 and July 2012 (Additional file 1).
The median age of the patient cohort was 64 years (range:
44–82 years), with 16 females and 26 males included in
the study. Thirty-two individuals were classified as PMF,
five had post-polycythaemia vera MF (PPV-MF) and five
had post-essential thrombocythaemia MF (PET-MF). At
the time of initial sample collection, all patients were in
the fibrotic phase of the disease with no evidence of leu-
kaemic transformation.
Polyploidy in MF associates with a high representation of
1q gain
A polyploid subclone was detected in nine MF patients
by karyotype analysis (Case nos. 1–9, Additional files 1
and 2). Seven cases were classified as PMF, one as PPV-
MF and one with PET-MF. At the commencement of the
study three patients were being treated with hydroxyurea,
one with interferon, one with thalidomide and one with
aspirin. Three patients were asymptomatic and untreated.
Two polyploid groups were noted: a tetraploid (4n) group
and a mixed (4n/8n) ploidy group. Polyploidy was detected
in both colcemid and vinblastine-colchicine arrested PB
cultures.
Case nos. 1–4 (Additional file 2) showed an abnormal
near-diploid clone with gain of 1q derived from an unbal-
anced translocation. These clones were present at initial
diagnosis in two of the patients studied (Case nos. 1, 2), and
at first successful cytogenetic investigation in Case no. 4. A
sample from the fourth patient (Case no. 3) was not cy-
togenetically evaluated at diagnosis but showed the der
(6)t(1;6)(q21;p21) as the sole karyotypic change on the ini-
tial cytogenetic investigation in 2008. Serial cytogenetic
analyses indicated that a tetraploid subclone developed sub-
sequently in all four cases after a period of 5–8 months
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and representative karyotypes are shown for each case in
Figure 1. One case showed mixed ploidy with an interstitial
duplication on 1q (Case no. 5) and one case with a complex
karyotype showed the same interstitial dup(1q) in a minor
tetraploid cell line (Case no. 6). Case nos. 7–9 showed poly-
ploidy without structural chromosome abnormalities. The
size of the polyploid clone ranged from 10% to 65% of
metaphases analysed (median: 25%).
Polyploid clones were persistent over time, and con-
firmed in both PB and BM in five cases (nos. 2, 3, 5, 7
and 8, Additional file 2). Follow up cytogenetic analysis
showed further karyotypic abnormalities. One patient
showed emergence of a hyperdiploid cell line (Case no. 2),
and two patients subsequently acquired minor subclones
with possible duplication of 6p (Case no. 1), and the t(6;9)
(p22;q34) (Case no. 4) (Figure 1).Figure 1 Karyotypes from Case nos. 1–4 (A - D, respectively) showing
on the right hand karyotype. A) Reciprocal translocation t(1;9) with two addit
on 6p prior to tetraploidisation. B) Two unbalanced translocations showing tr
interstitial deletion on 13q. C) The der(6)t(1;6) resulting in gain of 1q material
chromosome 20 was random). D) Complex karyotype showing the additiona
and 7p. Gain of 8, pericentric inversion 12 and deletion 22q are also evident. TSNP array analysis detects further genomic changes
Single nucleotide polymorphism array (SNPa) analysis was
performed on a total of 16 cases. Eight of the nine poly-
ploid cases were studied and results were compared to
SNPa on eight MF cases without polyploidy (Additional
files 3 and 4). All unbalanced karyotypic abnormalities
were detected by SNPa, while minor subclones, balanced
rearrangements and polyploidy were not detected using
this approach.
Polyploid cohort
The polyploid samples showed a median of three aberra-
tions per patient (range: 0–8). Twenty six changes in total
were detected. Two samples showed no abnormalities by
SNPa (Case nos. 7 and 8). For Case nos. 1–3 and 5, no
additional copy number changes were detected by SNPa in
genomic segments flanking the centromeric region on theunbalanced 1q arm translocations. Serial tetraploidisation is shown
ional copies of the derivative (1q)t(1;9) with subsequent rearrangement
anslocation of 1q with the der(18)t(1;18) and der(20)t(1;20) as well as an
and loss of distal 6p as the sole karyotypic abnormality (loss of
l derivative (1q) from the der(1;7)(q10;p10) resulting in gain of both 1q
he tetraploid karyotype shows acquisition of the t(6;9)(p22;q34).
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gion 1q21.1-32.1 contains an estimated 61.81 Mb of DNA
(Additional file 4), and 2,807 known genes (http://genome.
ucsc.edu, 21/04/2013). Twenty two genes on1q are listed in
the Cancer Genome Census including PDE4DIP, ARNT,
NTRK1, PBX1, PRCC, PMX, ABL2, TPR andMDM4.
Figure 2 shows SNPa profiles of chromosome 6 in
three of the 16 SNPa cases. The breakpoint at 6p22.1 as-
sociated with the der(6)t(1;6)(q21;p22) in Case no. 3 re-
sulted in a 27 Mb deletion from 6p22.2 to 6pter and
encompasses the DEK oncogene as well as JARID2, a
member of the polycomb repressor complex 2 cluster of
genes known to be implicated in MPN. A long 4.5 Mb
stretch of copy neutral loss of heterozygosity (CN-LOH)
was also detected in this case, extending from the 6p22.1
breakpoint toward the centromere to band p21.33
(Additional file 4). This segment houses the chromatin
modifier gene HIST1H4I and the transcription factor
POUF5I. A second case (Case no. 1) showed a 3.8 Mb CN-
LOH at 6p, extending from 6p21.1 to 6p12.3 (Additional file
4) and encompassing CENPQ, involved with chromosome
separation at mitosis. The latter patient subsequently ac-
quired a structural karyotypic rearrangement in a subclone
involving the more telomeric band 6p25 (Additional file 2).Figure 2 Abnormalities detected by SNPa on chromosome 6p. SNPa p
(red) on three cases with abnormalities on 6p. Segments showing CN-LOH
6p on the der(6)t(1;6) flanked by a region of CN-LOH; Case no. 20, regions
and Case no. 22, complex changes involving regions of both deletion andAdditional copy number changes detected by SNPa but
not visible by karyotyping included, in Case no. 2, deletion
of a 3.9 Mb region on distal 17q within the q25.1-q25.3
interval that houses SRSF2 known to harbour mutations
with poor prognostic impact in PMF and myelodysplastic
syndrome (MDS) [16]. In the same patient, duplication of
a 13.8 Mb segment on distal 20q extended from q13.13 to
qter (Additional file 4), including the mitotic kinase gene,
Aurora Kinase A (AURKA) (Figure 3A,B). A 1.6 Mb inter-
stitial deletion involving the 22q12.1-q12.2 region was de-
tected by SNPa in Case no. 5 (Figure 3C) and included four
cancer related genes: MN1, NF2, CHEK2 and EWSR1. In
Case no. 6, copy number gain at 16q12.1→q12.2 spanned
TOX3 (refer below). Case no. 9 with numerical ploidy
changes alone shown by karyotyping (Additional file 2) re-
vealed large stretches of mosaic CN-LOH on terminal 2p,
9p and 17q (Additional file 4, Figure 3D). In two cases,
SNPa analysis identified CN-LOH involving part of 14q
(Case no. 2, bands 14q24.2 to q31.3) or entire 14q (Case no.
5, bands q11.2 to q32.33) (Additional file 4, Figure 3E,F).
Non-polyploid cohort
Eight non-polyploid cases were studied further by SNPa
(NP-SNPa) (Additional file 4). Four cases showed arofiles showing changes in B allele frequency (blue) and LogR ratio
are denoted by an arrow. From top: Case no. 3, deletion of terminal
of mosaic CN-LOH occurring at the terminal end as well as interstitially,
amplification from 6p24.1 to 6q14.
Figure 3 Abnormalities detected by SNPa not observed by karyotyping. SNPa profiles showing changes in B allele frequency (blue) and LogR
ratio (red) consistent with (A-C) additional copy number changes not observed on the karyotype involving deletion on 17q and duplication on 20q
from Case no. 2 and deletion on 22q from Case no. 5; (D-F) mosaic CN-LOH involving terminal 2p (Case no 9) and terminal 9p (Case no. 2) as well as
CN-LOH of the entire 14q arm in 100% of DNA from Case no. 5; (G-H) metaphase FISH analysis of Case no. 2 showing the 20q subtelomere (orange
signals) on the chromosome 18 (aqua signals) segment of the der(18)t(1;18) (red arrow) and also on the derivative 20 from the t(1;20) (blue arrow).
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the Y. Three cases showed an abnormal karyotype with
sole del(13q), sole inv(3q) and loss of chromosome 18 as
well as a marker chromosome respectively. Cytogenetic
studies in one case failed to yield metaphase cells.The eight NP-SNPa cases showed a median of two ab-
errations per sample (range: 0–10). Twenty genomic
changes were detected overall. One sample showed a
complex karyotype with 10 changes alone attributed to
this one sample. Three samples showed no abnormalities
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detected in two cases including for one case as a sole ab-
normality (Case no. 21), and complex abnormalities on
6p were detected in a further two cases (nos. 20 and 22)
encompassing large genomic regions (Additional file 4).
The remaining abnormalities were found in single
cases. Case no. 31 with a normal karyotype showed a
large block of CN-LOH on 11q accompanied by copy
number loss flanking the immediate proximal 11q re-
gion. Case no. 39 had an unsuccessful karyotype and
showed the del(20q) and a 480Kb gain on 1p31.1 in-
volving only the NEGR1 gene. Interestingly, Case no.
22 with loss of chromosome18/+marker as the only
karyotypic abnormality in two serial analyses showed
significant additional changes on SNPa including dupli-
cation of 5p with concurrent loss of 5q, complex
changes on 6p (DEK) and deletion of small regions
within 6q24.1 (NMBR), 11q14.1 (DGL2) and 12q15
(MDM2), deletion of 17p (TP53) and multiple gains on
21q (ERG, RUNX1). In addition, chromosome 18q
showed CN-LOH involving the q11.2q12.1 region and
concurrent deletion of 18q12→qter, with the ASXL3
gene located at the 18q12 breakpoint junction. This lat-
ter finding most likely reflects composition of the
marker chromosome detected on the karyotype. The
disease progressed within the study period and the pa-
tient subsequently died.
Recurring changes observed in two or more samples
across the eight patients analysed in the polyploid cases
incorporating both SNPa and karyotyping data involved
gains on 1q (six cases) as well as loss on 22q (two cases)
and rearrangements of distal 6p (three cases) (Table 1).
CN-LOH involving 6p (two cases), 14q (two cases), the
commonly described CN-LOH9p (two cases) and ampli-
fication of 9p (one case) involving the JAK2 locus in
MPN were also detected using one or both of these
methods. The non polyploid group showed recurring
changes on 6p (two cases), 9p (two cases) and one case
with 22q CN-LOH.Table 1 Common abnormalities in the polyploid group
on combining SNPa and karyotyping data
Chromosome Abnormality Cytoband interval No. of cases
1 Gain q21.1-q44 4
1 Gain q21.1-q32.1 2
9 Gain/LOH p22.3-p24.3 3
6p aberrations Gain/loss/other p12.3-p21.1 3
6p LOH p12.3-p22.2 2
22 Loss q21.1-q21.2 2
14 LOH q24.2-q31.3 1
14 LOH q11.2-q32.33 1Fluorescent in situ hybridisation (FISH) confirms SNPa
findings and highlights further complex changes
Selected additional abnormalities detected by SNPa were
verified by FISH. In Case no. 2, FISH analysis on cul-
tured cells showed mosaicism of 66% for loss on 17q
and 44% for gain of 20q, and in Case no. 5, 90% for loss
on 22q. The change in the SNPa B allele frequency (BAF)
plots derived from granulocytic DNA corresponded to
65% (17q), 40% (20q) and 90% (22q) mosaicism (Figure 3,
A-C), further emphasising the utility of SNPa in samples
with heterogeneous cell populations. In Case no. 2, FISH
analysis also showed that additional 20q material identified
by karyotyping (Additional files 1, 2; Figure 1B) was lo-
cated on the der(18) involved with the t(1;18) in an un-
usual three way translocation (Figure 3, G-H). In this
rearrangement, the distal segment of 20q together with the
translocated 1q was duplicated on the der(18p). The dupli-
cated 20q region was 13.8 Mb in length (Additional file 2,
Figure 3B). No deletion on 18p was evident by SNPa. The
differing size of the FISH clones showing del(17q) and gain
of 20q in Case no. 2 is indicative of clonal divergence.
Centrosome studies
Centrosome studies on CD34 cells of five cases with MF
showed no structural centrosome abnormalities (data not
shown).
Micronucleus studies
Viable mononuclear cells were available from Case no. 1
for additional studies using the micronucleus assay. As
illustrated in Figure 4, a proportion of mononuclear cells
(60/1000 nuclei) showed chromosome expulsion by the
formation of huge nuclear bulbs (Figure 4, A-B). Bi-
nucleate cells (15/500 binucleate nuclei) also showed ex-
pulsion of chromosomal material by the formation of
micronuclei (Figure 4C). As shown in Figure 4D, un-
equal cell division was observed in binucleate daughter
cells using FISH probes specific to 1p and 1q providing
evidence for mitotic defects.
JAK2V617F mutation studies, biological correlates
and outcome
Five of nine polyploid cases (56%) showed the JAK2 mu-
tation (Additional file 4). Four were from the tetraploid
group (Case nos. 1, 2, 4 and 6) and one from the mixed
ploidy group (Case no. 9). Of the remaining 33 non-
polyploid cases, 22 were JAK2 mutation-positive (67%).
Transformation to blast phase occurred in three of the
nine polyploid cases and occurred within a median of
12 months from detection of myelofibrosis. Five patients
showed disease symptoms associated with either a cyto-
paenia, bone marrow failure, progressive splenomegaly
and/or karyotype evolution (Additional files 2 and 4). One
patient (Case no. 9) remains in stable chronic phase. A
BA
DC
Figure 4 Fluorescent in situ hybridisation analysis Cytochalasin B treated mononuclear cells from Case no. 1. A) FISH image showing
multiple chromosomes contained in the nuclear bulge using an all chromosome alpha satellite probe (green). B) two signals specific to the 1p
arm (orange) and one signal specific to the 1q arm (green) present in the nuclear bulge while the larger nucleus showed four signal copies for 1q and
two signal copies for 1p that correspond to the karyotype in Figure 1A (left image. C) FISH studies on binucleate daughter cells using an all
chromosome alpha satellite FISH probe (green) showing expulsion of chromosome material from the binucleate cell to the micronucleus. D) FISH
signal pattern for 1p and 1q arm probes showing unequal signal distribution of 1p and 1q in the two daughter nuclei and in the micronucleus.
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polyploid group and the rest of the cohort of 42 patients
showed a median survival of 4.7 years for the polyploid
group and 9.7 years for the remainder of the group (data
not shown). Two patients in the non polyploid group were
lost to follow up. The log rank test showed no significant
statistical difference between the two groups (P = 0.096).
Tetraploidy was associated with a younger median age
(54 years) relative to the whole cohort of 42 patients
(68 years), and five of the nine patients with polyploidy
underwent an allogeneic BM transplant. Two of the five pa-
tients survived at follow up (follow up range: 5 years and
12 months respectively). Two further cases received sup-
portive care but died. In Case no. 3 with the der(6)t(1;6) the
patient was in stable chronic phase for 16 years prior to the
study but has since become transfusion dependent. Only
one patient (Case no. 25) from the NP-SNPa group trans-
formed to post-MPN blast phase while a further two cases
(nos. 20 and 22) showed advanced disease with additional
complex genetics changes by SNPa. All three patients sub-
sequently died. The remaining five patients from the NP-
SNPa group are alive including one who received a BM
transplant and remains alive at 4 years post-transplant.Discussion
There have been few reports describing polyploid karyo-
types in MPN. An 8n or near 8n karyotype was reported
in one case each of MF and ET [17,18] and, more re-
cently, a single case of near tetraploidy was recorded by
Djordjevic et al. [11] in PMF. The increased detection of
polyploidy in our cohort may be attributed to several
factors, including: (i) the relatively low disease incidence
and only recent inclusion of cytogenetic data in disease
classification systems; (ii) the availability of sufficient num-
bers of metaphases for an extended analysis in order to
define the presence of the polyploid clones and detailed
follow-up cytogenetic studies that were not always achiev-
able in reported cytogenetic studies done on fibrotic BM;
iii) the possibility of a decreased sensitivity in some sam-
ples to the activity of spindle poisons leading to failure of
mitotic arrest and the generation of polyploid metaphases,
and iv) unique as yet unknown biological factors in the
subject population.
Micronucleus analysis of one of our polyploid cases
provided some insight into the pathophysiology of the
polyploidy, showing elimination of chromosome material
by the formation of micronuclei and large nuclear
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ism of polyploid rescue [19].
Overall, our cytogenetic studies have shown a striking
high frequency of gain of 1q material, evident in six of
nine polyploid cases. Whereas gain of 1q has been found
commonly in PMF as unbalanced 1q arm translocations
or interstitial duplication, the association with polyploidy
has not previously been reported in MPN [20-23]. Due
to the large size of the genomic imbalances, identifica-
tion of candidate genes on 1q in MPN has been difficult
to ascertain and gene associations remain to be clarified.
Recent reports in the literature have highlighted the role
of the MDM4 gene in MPN contained in the commonly
duplicated 1q32 region [24,25]. The MDM4 protein binds
directly with TP53 and acts as a negative regulator of
TP53. Over expression of MDM4 is a potent inhibitor of
TP53 leading to the accumulation of DNA damage and
genomic instability. PDE4DIP, PRCC and ABL2 on 1q close
to the heterochromatin are associated with cell division,
play a role in centrosome anchorage, mitotic checkpoint or
microtubule binding and may be implicated in the develop-
ment of polyploidy. Notably, the presence of chromosome
aneuploidy or large chromosome imbalances are also
known to give rise to neoplasia, genomic instability and
polyploidy [15].
High hyperdiploidy (>67 chromosomes) in childhood
acute lymphoblastic leukaemia (ALL) has been described
in association with gain of 1q in 10-15% of cases and has
been widely studied in haematological malignancies in
relation to ploidy level and cytogenetic abnormalities.
Gain of the 1q22-32.3 region was shown to be implicated
and contains the B4GALT3, DAP3, RGS16, MEM183A,
and UCK2 genes [26,27]. Microdeletion studies by Paulsen
et al. [28] using genome wide array analysis showed
involvement of 7p12.2 (IKZF1), 9p21.3 (CDKN2A), 9p13.2
(PAX5), 12p13.2 (ETV6), 13q14 (RB1), 19p13.3 (TCF3) in
association with hyperdiploid ALL. These regions bear
some similarity to commonly affected regions reported in
MPN [29]. In addition, gene mutations of FLT3 (10-25%),
KRAS/NRAS (15-30%) and PTPN11 (10-15%) have also
been detected in hyperdiploid ALL [30]. In a different
report, Paulson et al. [31] studied global epigenetic changes
and found hyper methylation of the CpG regions of the
CADM1, ESR1, FHT, RARB and WNT5A genes in more
than 50% of hyperdiploid cases, showing a high propensity
for epigenetic phenomenon in this ploidy group. The role
of epigenetics in MF has been increasingly shown and the
list of associated genes continues to grow although all the
above genes have not been described in PMF [6,29].
Multiple myeloma is another haematological disease
showing strong association with chromosome hyperdi-
ploidy and frequent gain of 1q/dup1q as described in
59% of cases in the study by Marzin et al. [32]. Whole arm
translocations were frequently associated with jumpingtranslocations involving the whole 1q arm as the donor
chromosome and involved the pericentromeric regions in
46% and the telomeric regions in 40% of recipient chromo-
somes. The proposed mechanism for the latter observation
was based on the decondensation of the pericentromeric
heterochromatin that favoured translocation to other sites
of homologous repetitive sequences in the genome. Dupli-
cation of 1q occurred preferentially in the 1q21q22 and
1q31q44 regions in their study. This bears significance in
regard to the mechanism related to the genetic instability
and complex changes unmasked in Case no. 2 of our study
that appear to involve translocation of the 20q subtelo-
mere with the 1q heterochromatic region.
Of additional interest is the report by Silva et al. [33]
on four infants with Down syndrome with gain of 1q
that developed acute megakaryocytic leukaemia and pro-
vides some indication of a possible association between
genes on chromosome 1q and megakaryocyte growth and
development.
Abnormalities on 6p were a further frequent change,
found in five of the 16 cases analysed using SNPa and in-
volving gain, loss, translocation, CN-LOH or a combination
(Additional file 4). Whereas the der(6)t(1;6) is a possible
primary cytogenetic change in MF, the add(6p) and t(6;9)
observed in our polyploid cases have been associated
with a more progressive disease stage [34,35]. In support
of these associations, two of our cases from the non-
polyploid group with complex changes on 6p showed
progressive MF. Three cases (two polyploid, one non-
polyploid) showed SNPa/chromosome rearrangement pos-
sibly involving the DEK oncogene locus, known to be
implicated in acute myeloid leukaemia and originally char-
acterised as a result of DEK/NUP214 fusion associated
with the t(6;9) in AML. DEK has also been implicated in
DNA damage repair and signalling [36].
Studies in the literature using SNPa show a marked
variability and range in the types of genetic abnormal-
ities detected in MPN. Despite this variation, a pattern
of common changes is emerging as more studies are
undertaken. Stegelman et al. [37] found no differences in
the pattern of genetic abnormalities that could distinguish
the classical MPN subgroups in 151 patients studied by
SNPa. In that series, 45 patients were described with PMF
and 14 patients with sMF. Recurrent copy number changes
in PMF involved +1q, +8 and del(20q) in addition to CN-
LOH on 9p, whereas common changes affecting sMF cases
included +9, del(17q11.2), del(20q) and CN-LOH 9p. The
remaining abnormalities detected were restricted to single
cases [37]. Kawamata et al. [38] studied 16 patients with
PMF and reported the del(13q), CN-LOH on 1p and CN-
LOH on 9p as recurrent changes with the remaining ab-
normalities in single cases alone.
Of our 16 MF cases analysed using SNPa, CN-LOH was
detected at one or more chromosomal regions in roughly
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polyploid (4/8 cases) cohorts. Although we found no par-
ticular association of specific CN-LOH regions with either
group, some recurring observations are of note. These in-
clude CN-LOH of 9p in three cases, all overlapping the
JAK2 locus and all positive for the JAK2V617F mutation,
an observation consistent with published findings [37,38].
CN-LOH also involved distinct regions of 6p in two cases,
a finding of interest given the high frequency of 6p aberra-
tions observed in our MF karyotypes overall, and by SNPa.
In single cases, CN-LOH also affected other chromosomal
regions, including 11q, 14q, 18q and 22q, all of which have
been previously reported in isolated MF patients from
different cohorts by others [25,37-40]. An interesting ob-
servation in our cases was the presence of genes involved
in DNA damage repair and cell cycle regulation repre-
sented in most regions of CN-LOH, i.e. MSH6, MSH2
(2p), FANCE (6p), FANCG (9p), CHECK1 (11q), RAD51L1
(14q) and CHECK2 (22q). This may reflect an underlying
defect in the DNA damage repair pathway and may ex-
plain the widespread nature of the genomic defects ob-
served in MF.
Small regions of copy number aberration (loss, gain,
structural interruption) identified using SNPa bring focus
to individual genes as candidate oncogenes or tumour sup-
pressor genes possibly underlying the biology of MF. Of
our 16 MF cases analysed using SNPa, two showed dele-
tions involving 11q14 and the DLG2 gene, which encodes a
scaffolding protein involved in cell signalling, and this was
the sole gene affected in one case. NEGR1 (gain-1p31.1),
NMBR (loss-6q24.1),TOX3 (gain-16q22) and ASXL3 (inter-
ruption-18q21.1) were sole genes contained in regions of
copy number change observed in single cases. NEGR1 is
implicated in cell adhesion, NMBR is a strong mitogen and
growth factor implicated in solid cancers, the TOX3 protein
is involved with chromatin structure and plays a role in
the unwinding and folding of DNA, and ASXL3 belongs
to the Additional Sex Combs-like family of three chro-
matin modifier genes of which ASXL1 is commonly de-
scribed in PMF [29].
Few of these genes have been completely characterised,
and their role, if any, in MF or other haematological neo-
plasms remains to be determined. Nonetheless, as descrip-
tions of clinical phenotypes associated with MF become
increasingly refined, recurring alterations may eventually
be associated with specific disease subsets. Towards this
end, more recent studies have focused on the clinical stage
associated with genetic abnormalities observed by SNPa
[24,41]. In a series of 408 samples, Klampfl et al. [24] re-
ported that changes involving 1q and 9p were strongly as-
sociated with sMF or progression to accelerated phase
(AP) whereas, changes involving 1q, 3q, 5q, 6p, 7p, 7q,
19q, and 22q were associated with post-MPN AML when
compared to chronic phase MPN. No associations werefound by Klampfl and co-workers that distinguished sMF/
AP from post MPN AML. In our series of nine polyploid
MF cases, the common abnormalities detected on com-
bining SNP and karyotype data included gains affecting
1q, 6p and 9p, and loss/LOH affecting 6p, 9p, 22q and
14q, findings that concur with the above earlier reports of
non-polyploid patient series. These patterns of genetic
changes are also similar to the SNPa profiles reported by
Gondek et al. [39] that showed an overlap between MPN,
MDS and MDS related AML [39,42].
In our series, disease evolution in the polyploid group
occurred after a much shorter disease duration. This was
reflected in patients both with and without structural kar-
yotype abnormalities, with the exception of one case har-
bouring a der (6) t (1;6) who showed a disease duration of
16 years and who does not appear to follow the progressive
disease course typical of patients with additional changes
to 6p [41]. The monosomal karyotype (case no. 6) and the
inversion 3 (case no. 25) were associated with a dismal
outcome as reported previously by other investigators
[43,44]. Two polyploid cases showed no abnormalities by
either karyotyping or SNPa, a finding possibly reflecting
the limitations of genomic resolution in our analysis or al-
ternative disease mechanisms.
Conclusions
In this study we found that SNPa with a medium density
array platform using DNA purified from PB samples was
sensitive to detect known and additional submicroscopic
changes in MF, including CN-LOH and an assessment
of the degree of clonal mosaicism. However, minor sub-
clones, balanced rearrangements and polyploidy were
not detected by SNPa. Overall, our findings suggest that
polyploid subclones are more frequent in the PB of pa-
tients with MF than previously known and demonstrate
that gain of 1q appears to be a common association.
Methods
Patients
Written consent was obtained from all patients accord-
ing to the research protocol approved by the Northern
Sydney Human Research Ethics Committee in accord-
ance with the Declaration of Helsinki. Patient disease
was classified according to current WHO recommenda-
tions [45]. Ten ml of PB was collected in heparin and
EDTA on 42 consecutive patients diagnosed with MF
(Additional file 1). In some cases, BM was additionally,
or alternatively, collected for the purpose of routine pa-
tient care. Both sample types were collected at different
time points through the disease course (Additional file 2).
Chromosome analysis
Cultures were established from the buffy coat obtained
from 10 ml of heparinised PB or from freshly aspirated
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stimulation, metaphase cells harvested and slides pre-
pared using standardised protocols [46]. Two independent
harvests were carried out on each PB sample using colce-
mid (Life Technologies, USA) or vinblastine-colchicine
(United Biosciences, QLD, Australia) at a final concen-
tration of 2 μg/mL for 1 hour or 0.3 μg/mL overnight,
respectively. BM cultures were harvested using only vin
blastine-colchicine. Analysis of at least 20 GTL-banded
metaphase cells was attempted on each sample. Cytogen-
etic studies were performed at diagnosis or at follow up
on BM or PB samples submitted to the laboratory for rou-
tine clinical management. The ISCN 2013 cytogenetic no-
menclature was used to describe the karyotype [47].
CytoSNP12 array
Granulocytes from 10 ml of PB collected in EDTA were
separated by Ficoll density gradient centrifugation. DNA
was extracted from purified cells of eight MF patients
with a polyploid subclone using the Qiagen Puregene kit
(Valencia, CA). Case no. 4 was not further investigated
by SNPa due to insufficient sample. Eight age- and sex-
matched MF cases without polyploidy, selected from our
total cohort of 42 cases, were also studied using SNPa for
comparison. DNA was processed for the HumanCytoSNP-
12 BeadChip assay by the Australian Genome Research
Foundation according to the manufacturer’s instructions
(Illumina, San Diego, CA). Data analysis was undertaken
using GenomeStudio software version 2011.1 from Illu-
mina. Copy number changes and CN-LOH were deter-
mined by analysis of the LogR ratio and the BAF plots
generated by GenomeStudio. The median probe spacing
on the array was 6Kb, and 20 consecutive markers were re-
quired for a copy number change to be called for a deletion
or duplication. CN-LOH was called when a normal LogR
ratio of 0 was obtained and a BAF score of 0 and 1 with no
heterozygous calls at a BAF of 0.5. CN-LOH <5 Mb was
excluded unless it contained known regions of significance
to the sample population under study. Mosaicism was esti-
mated by visual inspection of the BAF and compared to
simulated plots as described by Nancarrow using the SID-
CON method [48]. The genome browser used for analysis
was set to build GRCh 37/Hg19 (http://genome.ucsc.edu).
Common copy number variants were excluded if listed in
the Database of Genomic Variants (http://dgv.tcag.ca) or if
present when compared to the PB DNA of 12 healthy con-
trols sourced from the HapMap sample data set provided
by Illumina. Germline changes cannot be totally excluded
as no matched germline patient DNA was available for
study by SNPa. Gene prioritisation was undertaken with
the aid of the Sanger Cancer Genome Census (http://www.
sanger.ac.uk/cosmic). Sole genes in regions of change or
genes described in published series relevant to PMF were
also included.Fluorescent in situ hybridisation (FISH)
Directly labelled DNA probes specific to the chromo-
some 1q pericentromeric region and to alpha satellite re-
gions of chromosomes 9 and 18 (Kreatech, Amsterdam,
Netherlands) were used to confirm breakpoints on the
derivatives 1q. The ON EWSR1 (22q12) Break probe
(Kreatech Diagnostics, Amsterdam, Netherlands), TelVy-
sion 20q SpectrumOrange (Abbott Molecular, Des Plaines,
IL), and BAC clones RP11-318A15 (17q25.1) and RP11-
398 J5 (17q25.3) (The Centre for Applied Genomics,
Toronto, Canada), were used to confirm SNPa findings.
Probes were applied to fixed cells prepared for chromosome
analysis from cultured PB buffy coat cells (refer above). The
FISH procedure was carried out by standardised protocols
as specified by the manufacturer with minor modifications.
Briefly, slides were pre-treated in 10% (w/v) pepsin/0.1 N
HCl for 13 minutes and probes hybridised overnight at
37°C. Post hybridisation procedures were carried out by
washing slides in 0.1 XSSC, pH7.2/0.3% NP40 (v/v) at
72°C for 2 minutes and then in 2XSSC, pH7.2/0.1%
NP40 at room temperature for 10 seconds. Slides were
counterstained using DAPI (125 ng/mL, Abbott Molecular,
Des Plaines, IL), and viewed under an Olympus BX61 fluor-
escence microscope equipped with excitation and emission
filters appropriate to the probe fluorophores used.
Centrosome studies
The technique for centrosome analysis was based on a
modification of the method of Gisselsson et al. [14].
Cytospins were prepared from CD34+ cells enriched from
PB buffy coat of five samples using microbead technology
(Miltenyi Biotec, Bergisch Gladbach, Germany), fixed in
100% methanol for 20 minutes and then air dried. Slides
were rehydrated in 1× phosphate buffered saline (PBS) for
10 minutes at room temperature, drained, then incubated
in 200 μL of 1% (w/v) bovine serum albumin (BSA)/PBS
for 15 minutes at 37°C in a humid chamber. After drain-
ing, 200 μL of 1% BSA/0.1% Triton X-100 (v/v)/PBS was
applied for 15 seconds, the slide quickly drained, and
200 μL of the primary antibody against gamma tubulin, a
centrosome specific protein (Santa Cruz Biotechnology,
Europe), applied for 30–60 minutes at room temperature
after diluting 1:40 (v/v) in 1% BSA/PBS. The slide was
washed thrice in PBS for 5 seconds each. The goat anti-
mouse IgG-FITC conjugate secondary antibody (sc-2080,
Santa Cruz Biotechnology, Dallas, Texas, USA) was diluted
1:40 in 1% BSA/PBS, 200 μL applied and the slide incu-
bated for 30–60 minutes at room temperature in the dark.
Slides were then washed in PBS and air dried in the dark.
Ten μL of DAPI (0.125 ng/μL) was applied as a counter-
stain and slides viewed immediately using the Olympus
BX61 fluorescence microscope equipped with FITC emis-
sion filters for visualisation. Nuclei (n = 500) were scored
for abnormalities in centrosome number and size.
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Mononuclear cells at a density of 0.5 ×106 cells/mL were
cultured after Ficoll gradient separation from PB and in-
cubated at 37°C. After 44 hours, cytochalasin B (Sigma
Aldrich) was added to a final concentration of 6 μg/mL for
a further 24 hours. The tubes were centrifuged to pellet the
sample and the supernatant removed. Cells were washed in
5 mL of PBS and centrifuged. The supernatant was re-
moved to 0.5 mL and the cell pellet carefully resuspended
in 100% methanol. Slides were prepared from the cell pellet
and stained in 10% (v/v) Leishman stain (POCD Healthcare,
Sydney, Australia) for 9 minutes. Slides were mounted on
coverslips and viewed by light microscopy. Nuclei (n =
1000) were scored for defects in mononucleate and binucle-
ate cells using the criteria outlined by Fenech et al. [49].JAK2V617F mutation studies
JAK2V617F DNA mutation studies were carried out using
a Taqman qualitative assay that required 100 ng patient
DNA extracted from granulocytes and primers specific for
the mutation. Methods were according to Kroger et al. [50].Statistical analysis
Survival curve analysis was undertaken using the Kaplan
Meier method. The log rank test was used to measure
the significance of survival curves obtained for the poly-
ploid group compared to the whole cohort.Additional files
Additional file 1: Patient characteristics and karyotypes of 42
consecutive cases. File contains case ID, disease classification, JAK2
mutation status, sex, age and karyotype of entire cohort.
Additional file 2: Serial karyotype analysis of polyploid group.
File contains dated serial karyotypes of the nine polyploid cases.
Additional file 3: Base pair co ordinates and chromosome location
of copy number changes. File lists all genetic co ordinates of changes
detected by SNP array.
Additional file 4: SNP array findings in 16 patients with
myelofibrosis. Tabular data combining patient disease characteristics,
karyotype and corresponding changes detected by SNP array in addition
to disease stage, subsequent therapy and survival outcome. Table also
lists associated genes of interest.Abbreviations
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